Edition:
India

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

69.75USD
9:00pm IST
Change (% chg)

$0.45 (+0.65%)
Prev Close
$69.30
Open
$70.10
Day's High
$70.10
Day's Low
$68.65
Volume
63,260
Avg. Vol
322,619
52-wk High
$84.35
52-wk Low
$47.79

Latest Key Developments (Source: Significant Developments)

Seattle Genetics Sees FY 2019 Revenue $790 Mln To $840 Mln
Friday, 8 Feb 2019 

Feb 7 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.SEES FY 2019 REVENUE $790 MILLION TO $840 MILLION.Q4 LOSS PER SHARE $0.75.Q4 EARNINGS PER SHARE ESTIMATE $-0.42 -- REFINITIV IBES DATA.TOTAL REVENUES IN Q4 INCREASED TO $174.5 MILLION COMPARED TO $129.6 MILLION.ADCETRIS NET SALES IN U.S. AND CANADA FOR Q4 WERE $132.1 MILLION, A 58 PERCENT INCREASE.SEES 2019 ADCETRIS NET PRODUCT SALES $610 MILLION TO $640 MILLION.SEES 2019 COLLABORATION AND LICENSE AGREEMENT REVENUES $95 MILLION TO $110 MILLION.SEES 2019 ROYALTY REVENUES $85 MILLION TO $90 MILLION.SEES 2019 RESEARCH AND DEVELOPMENT EXPENSES $600 MILLION TO $650 MILLION.SEES 2019 NON-CASH COSTS (PRIMARILY ATTRIBUTABLE TO SHARE BASED COMPENSATION) $135 MILLION TO $145 MILLION.  Full Article

Seattle Genetics Announces FDA Approval Of Adcetris (Brentuximab Vedotin)
Friday, 16 Nov 2018 

Nov 16 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) IN COMBINATION WITH CHEMOTHERAPY FOR ADULTS WITH PREVIOUSLY UNTREATED SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA OR OTHER CD30-EXPRESSING PERIPHERAL T-CELL LYMPHOMAS.  Full Article

Seattle Genetics Q2 Earnings Per Share $0.47
Friday, 27 Jul 2018 

July 26 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 EARNINGS PER SHARE $0.47.Q2 EARNINGS PER SHARE VIEW $-0.39 -- THOMSON REUTERS I/B/E/S.TOTAL REVENUES IN Q2 INCREASED TO $170.2 MILLION COMPARED TO $108.2 MILLION.COMPANY IS INCREASING COLLABORATION REVENUE GUIDANCE FOR FULL YEAR IN 2018 TO A RANGE OF $65 MILLION TO $75 MILLION.AS OF JUNE 30, 2018, SEATTLE GENETICS HAD $457.8 MILLION IN CASH AND INVESTMENTS.FOR THIRD QUARTER OF 2018, CO EXPECTS SALES OF ADCETRIS TO BE IN THE RANGE OF $130 MILLION TO $135 MILLION..  Full Article

Seattle Genetics Cuts Stake In Immunomedics To 4.9 Pct As From 7.3 Pct
Wednesday, 6 Jun 2018 

June 5 (Reuters) - Immunomedics Inc ::SEATTLE GENETICS INC CUTS STAKE IN IMMUNOMEDICS INC TO 4.9 PERCENT AS OF JUNE 4, 2018 FROM 7.3 PERCENT AS OF DECEMBER 5, 2017 - SEC FILING.  Full Article

Unum Therapeutics Sees IPO Of 5.8 Mln Shares Priced $12 - $14 Per Share
Monday, 19 Mar 2018 

March 19 (Reuters) - Seattle Genetics Inc ::UNUM THERAPEUTICS INC SEES IPO OF 5.8 MILLION SHARES OF COMMON STOCK PRICED TO BE BETWEEN $12.00 AND $14.00 PER SHARE - SEC FILING.UNUM THERAPEUTICS INC SAYS IT ADDS SUNTRUST ROBINSON HUMPHREY TO THE UNDERWRITERS TO THE IPO.UNUM THERAPEUTICS INC SAYS SEATTLE GENETICS HAS AGREED TO PURCHASE $5.0 MILLION OF SHARES OF COMMON STOCK AT IPO PRICE, IN PRIVATE PLACEMENT.  Full Article

Seattle Genetics Announces Expiration Of Hart-Scott-Rodino Waiting Period
Friday, 16 Feb 2018 

Feb 16 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD.SEATTLE GENETICS - ‍REQUIRED WAITING PERIOD UNDER HART-SCOTT-RODINO ACT REGARDING CO'S PROPOSED ACQUISITION OF CASCADIAN THERAPEUTICS EXPIRED ON FEB 15, 2018​.  Full Article

Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - PHARMA MAR SA ::LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES.SAYS WILL RECEIVE UPFRONT PAYMENT OF $5.0 MILLION ON SIGNING, FOLLOWED BY DEVELOPMENT MILESTONES IF A PRODUCT ENTERS CLINICAL DEVELOPMENT CONDUCTED BY SEATTLE GENETICS.IS ELIGIBLE FOR POTENTIAL APPROVAL AND SALES MILESTONES, ROYALTIES, ONCE PRODUCT GETS REGULATORY APPROVAL AND IS COMMERCIALIZED.  Full Article

Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
Friday, 9 Feb 2018 

Feb 9 (Reuters) - Pieris Pharmaceuticals Inc ::SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION.SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL PAY PIERIS A $30 MILLION UPFRONT FEE, TIERED ROYALTIES ON NET SALES UP TO LOW DOUBLE-DIGITS​.SEATTLE GENETICS - CO, PIERIS TO EVALUATE BISPECIFIC IMMUNO-ONCOLOGY AGENTS COMBINING PIERIS' ANTICALIN TECHNOLOGY WITH SOME OF CO'S CANCER-TARGETED ANTIBODIES.SEATTLE GENETICS - UNDER TERMS OF AGREEMENT CO TO PAY PIERIS UP TO $1.2 BILLION IN TOTAL SUCCESS-BASED PAYMENTS ACROSS THREE PRODUCT CANDIDATES.SEATTLE GENETICS INC - ‍SEATTLE GENETICS WILL SOLELY DEVELOP, FUND AND COMMERCIALIZE OTHER TWO PROGRAMS​.SEATTLE GENETICS-PIERIS PHARMA, CO HAVE ENTERED INTO AGREEMENT FOR DEVELOPING MULTIPLE TARGETED BISPECIFIC IMMUNO-ONCOLOGY TREATMENTS FOR BLOOD CANCERS.SEATTLE GENETICS INC - ‍PRIOR TO INITIATION OF A PIVOTAL TRIAL, PIERIS MAY OPT INTO GLOBAL CO-DEVELOPMENT AND U.S. COMMERCIALIZATION OF SECOND PROGRAM​.SEATTLE GENETICS - PRIOR TO INITIATION OF PIVOTAL TRIAL, PIERIS MAY OPT FOR A SHARE IN GLOBAL COSTS, PROFITS ON 50/50 BASIS FOR SECOND PROGRAM.  Full Article

Seattle Genetics Commences Tender Offer For Cascadian Therapeutics
Friday, 9 Feb 2018 

Feb 8 (Reuters) - Cascadian Therapeutics Inc ::SEATTLE GENETICS COMMENCES TENDER OFFER FOR CASCADIAN THERAPEUTICS, INC..SEATTLE GENETICS - BOARD OF DIRECTORS OF CASCADIAN THERAPEUTICS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS OF CASCADIAN THERAPEUTICS TENDER THEIR SHARES.  Full Article

Seattle Genetics Announces Pricing Of Public Offering Of Common Stock At $52 per Share
Thursday, 1 Feb 2018 

Feb 1 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 11.5 MILLION COMMON SHARES PRICED AT $52.00PER SHARE.  Full Article